Current Liabilities
Other accrued liabilities
Pfizer Other accrued liabilities increased by 3.5% to $20.11B in Q1 2026 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ4 2025
How to read this metric
Significant changes should be analyzed to determine if they represent one-time adjustments or shifts in operational expense timing.
Detailed definition
This represents miscellaneous short-term obligations that do not fall into standard categories like accounts payable or...
Peer comparison
Standard residual category; peers report this as other current liabilities.
Metric ID:
current_liabilities_other_liabilities_currentHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $19.43B | $20.11B |
| QoQ Change | — | +3.5% |
Range$19.43B – $20.11B
Other accrued liabilities at Other Companies
Frequently Asked Questions
- What is Pfizer's other accrued liabilities?
- Pfizer (PFE) reported other accrued liabilities of $20.11B in Q1 2026.
- What does other accrued liabilities mean?
- Miscellaneous short-term debts that do not fit into standard categories like accounts payable.